News
Weight loss drugs like semaglutide could add £4.5 billion to the UK economy annually, boosting productivity and reducing ...
10h
Zacks Investment Research on MSNLilly Down 17% Since Q1 Results: Should You Buy the Dip in LLY Stock?Eli Lilly and Company’s LLY shares have lost 17% so far in May. Lilly announced mixed earnings results on May 1. It missed ...
With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had ...
The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...
Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...
Eli Lilly announced that its obesity therapy Zepbound delivered superior outcomes versus Novo Nordisk’s Wegovy across five ...
In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...
At 72 weeks, participants using Zepbound saw an average weight-loss reduction of 20.2% versus 13.7% with Novo Nordisk’s own ...
The U.S. and China, after trade talks in Geneva, agreed to cut tariffs on each other by 115 percentage points, for at least 90 days. Treasury Secretary Scott Bessent further added that talks on ...
The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in ...
Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results